Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction

Trial Profile

Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Acronyms VCU-Alpha1RT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Dec 2013 Planned end date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 01 Dec 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top